Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent…

By L. Lombardo, Francis Y F Lee, Ping Chen, Derek J. Norris, J. Barrish, Kamelia Behnia, S. Castaneda, Lyndon A. M. Cornelius, J. Das, A. Doweyko and 17 more. Journal of Medicinal Chemistry, 2004

1,334 citations recorded by the source corpus.

Subfields: Ecology, Evolution, Behavior and Systematics, Hematology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/9842977ec6769ae2bbcfa324356fc872553a1362

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Priscilla L. Yang
2. Jianming Zhang
3. Nathanael S. Gray

Citations in the corpus

• Targeting cancer with small molecule kinase inhibitors (2009, positive): “aspx?CdrID=37862">imatinib -resistant CML, potently inhibits all nine members of the Src family of kinases (and numerous other tyrosine kinases), yet exhibits a more favourable side effect profile than conventional cytotoxic chemotherap”
• Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer (2010, background): “Dasatinib is an orally available TKI that inhibits the abl and src family tyrosine kinases at sub-nanomolar concentrations and is currently used in the treatment of chronic myelogenous leukemia [66, 67].”
• Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “, imatinib and dasatinib, produce more favorable outcome compared to conventional cytotoxic therapy [18, 19].”